Rocket Lab USA Inc vs Teladoc Health Inc — how do they compare? Rocket Lab USA Inc trades at $68.33 (market cap $43.74B), while Teladoc Health Inc trades at $5.75 (market cap $1.01B). The key difference: Rocket Lab USA Inc is far larger — about 43.3× Teladoc Health Inc's market cap, and Rocket Lab USA Inc is more actively traded (22,892,581 versus 4,668,477). Which is the better fit depends on your goals — on Pluang, investors hold Rocket Lab USA Inc for 29 Days and Teladoc Health Inc for 39 Days on average.
| RKLB | TDOC | |
|---|---|---|
Market Cap | $43.74B | $1.01B |
Volume | 22,892,581 | 4,668,477 |
Sector | Industrials | Health |
52-Week High | $150.23 | $9.72 |
52-Week Low | $39.48 | $4.47 |
Typical Hold Time | 29 Days | 39 Days |
Enterprise Value | $41.57B | $1.27B |
Signals from Pluang's Aura AI — not financial advice
Rocket Lab (RKLB) trades at $68.35, down 4.96% in the last session, reflecting a bearish technical trend. The company's fundamentals show strong revenue growth, with 2026 revenue projected at $769 million, but it remains unprofitable with a net loss of -$165 million. Recent positive news includes securing its largest-ever commercial Electron launch deal with Synspective, boosting its backlog to over 100 missions. Analyst sentiment is predominantly bullish, with a consensus price target of $107.00.
The outlook for RKLB hinges on execution of its growing launch backlog and path to profitability. Investment opportunity lies in its leading position in small satellite launch services and expanding spacecraft business. Key risks include intense competition from SpaceX, high cash burn, and reliance on future Neutron rocket success. The stock offers high growth potential but carries significant execution and valuation risks.
Teladoc Health (TDOC) trades at $5.67, showing modest daily gains but remains near multi-year lows with a bearish technical outlook. The company maintains strong revenue around $2.5B annually but continues to report net losses, with a -7.13% net margin in 2026. Recent management changes include the appointment of a new CFO, while analyst sentiment remains cautious despite a consensus price target of $8.83 representing 56% upside potential.
TDOC presents a high-risk opportunity with significant upside potential if the company can achieve profitability turnaround. The stock trades at discounted valuations (P/S 0.4x, P/B 0.77x) but faces execution risks from ongoing losses, BetterHelp segment challenges, and potential legal investigations. Free cash flow generation and integrated care growth provide stabilization, though sustained profitability remains the key catalyst needed for sustained recovery.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →